Medigene provides Q2 update and 6M report 2020
(WorldNews Health)

Martinsried/ Munich - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, today published its 6-Months Report 2020 with an overview on its business performance and financial results. The full version of the report can be downloaded here: https://www.medigene.com/investors-media/reports-presentations/ Prof. Dolores Schendel, CEO/CSO at Medigene: `We are in the fortunate position to report that our research and development projects have continued to progress uninterrupted over the past six months. With the start of our second clinical trial with T cell receptor (TCR) immunotherapy MDG1021 at the...